Establishment Labs (NASDAQ:ESTA) Sets New 12-Month High – Here’s Why

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares hit a new 52-week high on Wednesday . The company traded as high as $89.36 and last traded at $89.0290, with a volume of 117060 shares trading hands. The stock had previously closed at $87.01.

Analysts Set New Price Targets

ESTA has been the subject of several research analyst reports. Wall Street Zen lowered shares of Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Canaccord Genuity Group increased their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday. BTIG Research lifted their price objective on shares of Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, TD Cowen reiterated a “buy” rating on shares of Establishment Labs in a research report on Monday, June 8th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Establishment Labs currently has an average rating of “Moderate Buy” and a consensus price target of $87.14.

Establishment Labs Stock Up 2.1%

The stock has a 50-day moving average of $73.18 and a two-hundred day moving average of $70.22. The company has a market cap of $2.62 billion, a P/E ratio of -59.78 and a beta of 1.11. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The business had revenue of $59.88 million for the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The firm’s revenue was up 44.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.70) earnings per share. On average, research analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

Insider Activity

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the transaction, the director owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. This trade represents a 10.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 292,500 shares of company stock valued at $20,591,021. 9.99% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. KBC Group NV bought a new stake in shares of Establishment Labs in the 1st quarter valued at about $28,000. Quarry LP bought a new position in Establishment Labs during the 3rd quarter worth approximately $34,000. Kestra Advisory Services LLC bought a new position in Establishment Labs during the 4th quarter worth approximately $47,000. Osaic Holdings Inc. increased its stake in Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares during the period. Finally, MV Capital Management Inc. purchased a new position in Establishment Labs in the 4th quarter worth approximately $146,000. 72.91% of the stock is owned by institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.